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MRF4 negatively regulates adult skeletal muscle
growth by repressing MEF2 activity
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The myogenic regulatory factor MRF4 is highly expressed in adult skeletal muscle but its
function is unknown. Here we show that Mrf4 knockdown in adult muscle induces
hypertrophy and prevents denervation-induced atrophy. This effect is accompanied by
increased protein synthesis and widespread activation of muscle-speciﬁc genes, many of
which are targets of MEF2 transcription factors. MEF2-dependent genes represent the top-
ranking gene set enriched after Mrf4 RNAi and a MEF2 reporter is inhibited by co-transfected
MRF4 and activated by Mrf4 RNAi. The Mrf4 RNAi-dependent increase in ﬁbre size is pre-
vented by dominant negative MEF2, while constitutively active MEF2 is able to induce
myoﬁbre hypertrophy. The nuclear localization of the MEF2 corepressor HDAC4 is impaired
by Mrf4 knockdown, suggesting that MRF4 acts by stabilizing a repressor complex that
controls MEF2 activity. These ﬁndings open new perspectives in the search for therapeutic
targets to prevent muscle wasting, in particular sarcopenia and cachexia.
DOI: 10.1038/ncomms12397 OPEN
1 Venetian Institute of Molecular Medicine (VIMM), via Orus 2, 35129 Padova, Italy. 2Molecular Endocrinology, Institute for Diabetes and Obesity, Helmholtz
Zentrum Mu¨nchen, Business Campus Garching, Parkring 13, D-85748 Garching, Germany. 3Department of Biomedical Sciences, University of Padova,
via Ugo Bassi 58/B, 35131 Padova, Italy. 4 Center for Genome Research, Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287,
41125 Modena, Italy. 5 Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Universite´, INSERM, CNRS, 13288, Marseille, France. 6 Institute for Research
in Biomedicine (iBiMED), and Aveiro Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal. 7 Division of Cancer Biology, The Institute of
Cancer Research, Chester Beatty Laboratories, 237, Fulham Road, London SW3 61B, UK. 8Molecular Embryology Team, Centro Andaluz de Biologı´a del
Desarrollo, CSIC-UPO-JA, Carretera de Utrera Km1, 41013 Seville, Spain. * These authors contributed equally to this work. w Present addresses: Department of
Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany (M.M.); Faculty of Sport
Sciences, Waseda University, Mikajima 2-579-15, Tokorozawa, Saitama 359-1192, Japan (T.A.); Department of Neurosciences, Biomedicine and Movement
Sciences, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy (E.C.). Correspondence and requests for materials should be addressed to E.C.
(email: elisa.calabria@univr.it) or to S.S. (email: stefano.schiafﬁno@unipd.it).
NATURE COMMUNICATIONS | 7:12397 | DOI: 10.1038/ncomms12397 | www.nature.com/naturecommunications 1
T
he basic helix-loop-helix (bHLH) family of myogenic
regulatory factors (MRFs) comprises four members,
MyoD, myogenin, myogenic factor 5 (Myf5) and MRF4,
which play key roles in skeletal muscle commitment and
differentiation1. The MyoD and Myf5 genes are involved in
muscle commitment during embryogenesis, whereas myogenin
has a crucial downstream role in the differentiation of committed
muscle progenitors into myoﬁbres. Mrf4 differs from the other
family members in that it has a biphasic pattern of expression
during mouse development2. Mrf4 is transiently expressed at the
same time as Myf5 at the onset of myogenesis in the embryo3 and
can function as a determination gene, as some myogenesis takes
place in a double Myf5/MyoD mutant in which Mrf4 is not
compromised4. A later phase of Mrf4 expression starts during
fetal development and continues throughout postnatal stages and
is by far the predominant MRF expressed in adult muscle ﬁbres5.
However, the function of MRF4 in adult muscle is not known.
We sought to understand the role of MRF4 in adult skeletal
muscle using an RNA interference (RNAi) approach. Here we
show that Mrf4 knockdown in adult skeletal muscle causes a
striking increase in muscle ﬁbre size, suggesting that MRF4 is a
negative regulator of muscle growth. Muscle hypertrophy induced
byMrf4 RNAi is accompanied by increased expression of muscle-
speciﬁc genes, including those encoding proteins involved in the
sarcomere, the membrane cytoskeleton, the excitation–
contraction coupling apparatus and energy metabolism. This
effect is dependent on an increase in MEF2 transcriptional
activity and the consequent upregulation of MEF2 target genes.
We show that the hypertrophic effect of Mrf4 RNAi is abolished
by dominant negative MEF2, while myoﬁbre hypertrophy is
induced by constitutively active MEF2. The identiﬁcation of two
transcription factors that act together to regulate growth in adult
muscle raises interesting possibilities for the treatment of muscle
wasting conditions.
Results
Mrf4 RNAi induces adult muscle growth and protein synthesis.
Short hairpin RNA (shRNA) sequences targeting Mrf4 mRNA
were inserted into pSUPER plasmids and co-transfected in to
cultured HEK-293 cells together with a plasmid encoding myc-
tagged rat MRF4. A vector containing shRNA sequences targeting
LacZ was used as a negative control. Two Mrf4-speciﬁc shRNAs,
referred to as M1 and M2, were found to markedly decrease the
expression of MRF4 (Supplementary Fig. 1a) and were thus
selected for in vivo studies. Plasmids coding for M1 and M2 were
then electroporated in to rat muscles, together with a plasmid
encoding GFP. A marked decrease in nuclear staining for the
endogenous MRF4 was seen in transfected muscle ﬁbres, identi-
ﬁed by GFP expression, compared with untransfected ﬁbres
within the same muscles (Supplementary Fig. 1b). Unlike MyoD
and myogenin, which are prevalent in fast or slow muscles,
respectively, we found that MRF4 is expressed at similar RNA
and protein levels in the fast extensor digitorum longus (EDL)
and slow soleus (SOL) muscles (not shown), in agreement with
previous studies6,7. Therefore, we examined the effect of M1 and
M2 in both EDL and SOL muscles.
The most obvious change induced by MRF4 knockdown was
the marked hypertrophy of most transfected ﬁbres compared with
LacZ shRNA controls (Fig. 1a,b) and to non-transfected ﬁbres in
the same muscle (Fig. 1a and Supplementary Fig. 2). Muscle ﬁbre
hypertrophy was evident at 7 and 14 days post transfection in
both innervated and denervated muscles, denervation atrophy
being prevented by Mrf4 RNAi (Fig. 1b and Supplementary
Fig. 3). In contrast, muscle ﬁbre size was unaffected by
overexpression of Mrf4 in adult muscles (Fig. 1c). We also
examined the effects of Mrf4 knockdown and overexpression in
regenerating muscles. Regenerating muscle growth was strikingly
accelerated by Mrf4 knockdown, with ﬁbre size more than
doubled compared with controls (Fig. 1d and Supplementary
Fig. 4). A smaller but signiﬁcant change in the opposite direction
was induced by Mrf4 overexpression in regenerating muscle, with
ﬁbre size being reduced by about 20% compared with control
(Fig. 1e).
To validate the speciﬁcity of our RNAi experiments and rule
out the possibility that the observed changes were due to off-
target effects, we performed rescue experiments with RNAi-
resistant target genes. The sequence recognized by M1 shRNA in
rat Mrf4 has a single base difference in human Mrf4, so that
expression of the human gene is not silenced by M1 in cultured
HEK-293 cells (Fig. 1f). In vivo transfection experiments showed
that the increase in ﬁbre size induced by Mrf4 RNAi was
completely abrogated when a plasmid encoding human Mrf4 was
co-transfected with M1 (Fig. 1f). A similar rescue experiment
with identical results was performed with M2, using mouse Mrf4,
which is M2-resistant because of a two-base difference in the
sequence recognized by M2 shRNA (Fig. 1g). Next, we asked
whether the effect of Mrf4 knockdown on muscle growth is
speciﬁc for this member of the MRF family and tested the effect
of shRNAs targeting myogenin. However, no effect on muscle
ﬁbre size was observed when myogenin-speciﬁc shRNAs were
transfected in to adult skeletal muscle (Fig. 1h), in agreement with
the ﬁnding that muscle weight was unchanged by deletion of the
myogenin gene in adult innervated muscles using an inducible
knockout model8.
Muscle hypertrophy is always accompanied by increased
protein synthesis9. To monitor protein synthesis in transfected
muscles, we used a procedure based on the incorporation of
puromycin into nascent peptides10. As shown in Fig. 1i, Mrf4
RNAi induced a signiﬁcant increase in the amount of puromycin-
labelled peptides compared with LacZ RNAi controls. This
ﬁnding shows that protein synthesis is markedly increased during
muscle hypertrophy induced by loss of MRF4, as in other models
of muscle hypertrophy.
Muscle-speciﬁc genes are upregulated by Mrf4 knockdown. To
address the mechanism of muscle hypertrophy induced by Mrf4
knockdown, we performed microarray analysis of innervated and
denervated SOL muscles transfected with shRNA to Mrf4
(M1 sequence) and compared them with muscles transfected with
shRNA to LacZ and examined after 7 days. We ﬁrst examined
differentially expressed genes in the four experimental groups and
found that Mrf4 RNAi increased the expression of 677 genes and
decreased the expression of 782 genes compared with the control
LacZ RNAi (fold change 42 and adj. Po0.05) (Supplementary
Fig. 5 and Supplementary Data 1). The top signiﬁcant 100 genes
comprise 96 upregulated and only 4 downregulated genes
(Fig. 2a). As shown in the heatmaps, similar changes were
induced by Mrf4 knockdown in innervated and denervated
muscles.
Gene set enrichment analysis (GSEA) revealed that samples
transfected with shRNAs to Mrf4 showed marked enrichment of
gene sets involved in muscle contraction, excitation–contraction
coupling and energy metabolism (Fig. 2b). A representative
sample of muscle genes activated byMrf4 knockdown is shown in
Supplementary Table 1. Genes coding for the sarcomeric myosin
heavy chains (MyHCs) and myosin light chains were among the
most upregulated genes, with Myh1, Myh4 and Myh2, coding for
fast-type MyHC-2X, -2B and  2A, respectively, showing a
striking 76-, 45- and 29-fold induction, respectively (Fig. 2c). In
addition, genes coding for embryonic (Myh3), neonatal (Myh8)
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Figure 1 | Mrf4 RNAi induces myoﬁbre hypertrophy and protein synthesis in adult muscles. (a) Rat soleus muscles co-transfected with GFP and LacZ or
Mrf4 shRNAs and examined 14 days later. Scale bar, 100mm. Cross-sectional area (CSA) of transfected ﬁbres is shown below. Two hundred GFP-positive
ﬁbres from each muscle were analysed. (b) CSA of muscle ﬁbres in innervated or 7 d denervated SOL and EDL muscles transfected with two different Mrf4
shRNAs (M1 and M2). Values normalized to ﬁbres transfected with LacZ shRNAs in innervated muscles. Measures on 58 muscles, about 5 muscles per
group, 15,485 ﬁbres. (c) Mrf4 overexpression in adult SOL. CSA of muscle ﬁbres transfected with Mrf4 cDNA normalized to control muscles (n¼ 3).
(d) Fibre size is increased in regenerating SOL co-transfected at day 3 after injury with GFP and LacZ or Mrf4 shRNAs, and examined 7 days later. Scale bar
100mm. Right: CSA of regenerating ﬁbres transfected with Mrf4 shRNAs (M1) normalized to control (n¼ 3). (e) Fibre size is reduced by Mrf4
overexpression in regenerating muscle (n¼ 3). (f) Rescue experiment for M1. The sequence recognized by M1 shRNA in rat Mrf4 transcripts (rMrf4) has a
single base difference in human Mrf4 (hMrf4). hMrf4 is not silenced by M1 in HEK-293 cells (left), as shown by western blotting with anti-MRF4. Fibre
growth induced by M1 in 14 days denervated SOL is prevented by M1-resistant hMrf4 (right, n¼ 5). (g) Rescue experiment for M2. Same as in f, but using
M2 shRNA speciﬁc for rat Mrf4 and M2-resistant mouse Mrf4 (mMrf4) (n¼ 5). (h) Fibre size is not affected by myogenin knockdown. Left: HEK-293 cells
transfected with myogenin cDNA (MyoG) and co-transfected with two shRNAs targeting myogenin (MG1 and MG2). GFP was co-transfected to determine
transfection efﬁciency. Right: ﬁbre size in unchanged by MG1 (n¼ 3). (i) Increased Protein synthesis is increased in SOL by Mrf4 shRNAs (M1), as revealed
by puromycin incorporation and immunostaining for puromycin-labelled peptides. Quantiﬁcation is on the right (n¼4). Data are presented as
mean±s.e.m. from at least three independent experiments. Statistical analysis with Student’s two-tailed t-test (*Po0.05, **Po0.01, ***Po0.001).
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and extraocular MyHC (Myh13) were also signiﬁcantly upregu-
lated. The upregulation of some of these Myh genes was
conﬁrmed by qPCR (Fig. 2d and Supplementary Table 2).
A surprising effect of MRF4 knockdown was the upregulation
of genes speciﬁc for cardiac and smooth muscle tissue, including
Myh6 (a/cardiac MyHC), Tnni3 (cardiac troponin I), Myh11
(smooth muscle MyHC), Myh10 (nonmuscle MyHC IIB, also
expressed in smooth muscle), and Myl9 (smooth muscle myosin
light chain 2) (Fig. 2c,d). MyHC-a/cardiac, which is never
expressed in extrafusal ﬁbres of leg muscles, was occasionally
detected with a speciﬁc antibody in some transfected muscle
ﬁbres, which also contained MyHC-2A (Fig. 2e). However,
cardiac troponin I and MyHC-2B were not detected at the protein
level (Supplementary Fig. 6).
MEF2 target genes are upregulated by Mrf4 knockdown. GSEA
using TRANSFAC showed that gene sets enriched in both
innervated and denervated SOL muscles following Mrf4 knock-
down included genes putatively regulated by MYOD and myo-
genin (Supplementary Table 3). Myogenin but not MyoD
transcripts were signiﬁcantly upregulated in both innervated and
denervated muscles, as shown by qPCR analysis (Fig. 3a). How-
ever, the top-ranking gene set upregulated by Mrf4 knockdown
(normalised enrichment score (NES)¼ 2.4; false discovery rate
(FDR) o0.0001) was comprised of genes regulated by MEF2
factors (Supplementary Table 3). The transcript levels of Mef2d
were signiﬁcantly upregulated by Mrf4 RNAi in both innervated
and denervated muscles and those of Mef2a in innervated muscle
(Fig. 3a). By comparing the results obtained from GSEA
(TRANSFAC) and differential expression analysis we identiﬁed a
large group of MEF2 targets which were signiﬁcantly upregulated
by Mrf4 RNAi (Fig. 3b). Increased expression of some of these
genes was conﬁrmed by qPCR (Fig. 3c). Upregulated MEF2 tar-
gets include a large number of muscle genes encoding myoﬁ-
brillar and mitochondrial proteins (Supplementary Table 1 and
Supplementary Data 1). These results suggest that MEF2 is a
major factor in the reprogramming of muscle gene expression
induced by Mrf4 knockdown. Speciﬁcally, the fact that Mrf4
RNAi causes upregulation of MEF2 target genes suggests that
MRF4 acts as a repressor antagonizing MEF2 activity. To verify
the role of MEF2 factors in mediating the effects of MRF4
knockdown, we examined (i) the existence of a physical inter-
action between MRF4 and MEF2, (ii) the response of a MEF2
reporter gene to MRF4 knockdown and (iii) the effect of a
dominant negative MEF2 mutant on muscle growth induced by
MRF4 knockdown.
MRF4 interacts with MEF2 and represses MEF2 activity. It is
known that MyoD and myogenin, when bound to E proteins, can
physically interact and synergize with MEF2 factors to induce
activation of muscle-speciﬁc genes11. Importantly, MEF2 and
myogenin synergistically activate MEF2 reporters, even in the
absence of a functional E-box, while MEF2C can activate E-box-
dependent reporters. These ﬁndings support the notion that
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target genes, as determined by crossing the results obtained from GSEA (TRANSFAC) and differential expression analysis. Red and green colours represent
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activation of muscle gene expression is mediated by cooperative
protein–protein interactions between the two families of
transcription factors. However, the interaction between MRF4
and MEF2 has not been explored. To address this issue, we
performed co-immunoprecipitation experiments by transfecting
HEK-293 cells with plasmids encoding Flag-tagged MEF2C and
Myc-tagged MRF4 or Myc-tagged myogenin. As shown in Fig. 4a,
co-immunoprecipitation experiments conﬁrm the interaction
between MEF2 and myogenin, and support the existence of a
similar physical interaction between MEF2 and MRF4.
Next, we studied the effect of MRF4 on a MEF2-dependent
reporter. In HEK-293 cells, the reporter was transactivated by
myogenin, in agreement with previous studies11, but was
inhibited by MRF4 (Fig. 4b). In adult skeletal muscle, the
MEF2 reporter was likewise transactivated by myogenin but
strongly inhibited by MRF4 overexpression (Fig. 4c). An opposite
effect was induced by MRF4 knockdown: MEF2 reporter activity
was markedly increased by Mrf4 shRNA (M1), whereas it was
unaffected by shRNA against myogenin (Fig. 4d). A similar
increase in MEF2 reporter activity was induced by M2 shRNA to
rat MRF4 and this effect was completely abrogated by
co-transfection with the RNAi-resistant mouse Mrf4 (Fig. 4e).
The increase in MEF2 transcriptional activity induced by MRF4
knockdown was seen in both SOL and EDL muscles and was also
obvious in denervated muscles, which showed decreased MEF2
activity relative to control muscles (Supplementary Fig. 7).
To determine whether a speciﬁc MRF4 domain is involved in
the repression of the MEF2 reporter, we transfected both SOL and
EDL muscles with chimeric transgenes containing either the
MRF4 N-terminal domain linked to myogenin bHLH and
C-terminal domains, or the myogenin N-terminal domain linked
to MRF4 bHLH and C-terminal domains (Fig. 4f). Whereas the
response to the ﬁrst chimera is similar to that of myogenin, the
second chimera, containing the MRF4 C-terminal domain, has a
repressive effect on the MEF2 reporter, similar to that of MRF4
(Fig. 4g). These results suggest that the MRF4-dependent
repression of MEF2 transcriptional activity in adult skeletal
muscle is associated with the C-terminal domain of MRF4.
dnMEF2 prevents Mrf4 RNAi-dependent muscle hypertrophy.
To determine whether MEF2 is required for mediating myoﬁbre
hypertrophy induced by Mrf4 RNAi, we used a truncated
dominant negative MEF2 (dnMEF2, Fig. 5a), which abrogates
MEF2-dependent transcriptional activity in cardiac muscle of
transgenic mice12 and inhibits muscle-speciﬁc gene expression
and myotube formation in cultured skeletal muscle cells13. The
increase in ﬁbre size induced by Mrf4 RNAi was prevented by
co-transfection with dnMEF2 in both innervated and denervated
muscles (Fig. 5b). This experiment supports a necessary role of
MEF2 in mediating the effect of Mrf4 RNAi and at the same time
supports the existence of a direct link between MEF2 activity and
muscle ﬁbre growth in adult skeletal muscle. The following
experiment was aimed at validating the existence of this link.
caMEF2 induces myoﬁbre hypertrophy in adult skeletal muscle.
An inducible, constitutively active MEF2 (caMEF2) was used,
together with a DNA-binding-deﬁcient version of this construct
(D-caMEF2), to determine whether an increase in MEF2 tran-
scriptional activity is sufﬁcient to induce myoﬁbre hypertrophy in
adult skeletal muscle (Fig. 5a). In agreement with studies in
cultured neurons14, we found that caMEF2 was localized in
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co-immunoprecipitated with MRF4 or MyoG. (b) HEK-293 cells co-transfected with MEF2C, a MEF2-Luciferase reporter, containing three tandem copies of
the MEF2 site linked to luciferase, and either MyoD, myogenin or MRF4 (n¼ 3). (c) Adult SOL muscle transfected with a MEF2-Luciferase reporter were
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MRF4 (chimera 2). (g) SOL and EDL muscles were transfected with the MEF2 reporter and co-transfected with either myogenin, Mrf4 or chimeric
transgenes (n¼ 5). Data are presented as means±s.e.m. from at least three independent experiments. Statistical analysis was performed using Student’s
two-tailed t-test (*Po0.05, **Po0.01, ***Po0.001).
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myonuclei of transfected myoﬁbres in animals treated with
tamoxifen (Fig. 5c). Both innervated and denervated myoﬁbres
transfected with caMEF2, but not those transfected with
D-caMEF2, showed a signiﬁcant hypertrophy after treatment
with tamoxifen (Fig. 5d). In animals treated with oil vehicle rather
than tamoxifen, caMEF2 remained sequestered in the cytoplasm
and ﬁbre size was unchanged (Fig. 5e,f). These results indicate
that MEF2 transcriptional activation is sufﬁcient to induce
myoﬁbre hypertrophy in adult skeletal muscle.
MRF4 knockdown causes HDAC4 nuclear export. To identify
the mechanism of MEF2 repression by MRF4, we ﬁrst asked
whether MRF4 acts as a repressor per se. However, in agreement
with a previous study15, no repression was observed in a GAL4
DNA-binding system (Supplementary Fig. 8). Therefore we have
considered the possibility that MRF4 may act by affecting the
function of a MEF2 repressor. Class IIa histone deacetylases
(HDACs), such as HDAC4, are known to bind and repress MEF2
(ref. 16), and their function is controlled by nucleo-cytoplasmic
shuttling, with nuclear import leading to MEF2 repression and
nuclear export to MEF2 activation17. We observed a faint staining
of endogenous HDAC4 in both nuclei and cytoplasm of
innervated muscle ﬁbres, yet a marked nuclear accumulation of
HDAC4 in ﬁbres from denervated muscles (Fig. 6a,b). However,
the proportion of nuclear HDAC4 was signiﬁcantly less in both
innervated and denervated myoﬁbres transfected withMrf4 RNAi
compared to LacZ RNAi controls (Fig. 6c,d). The difference was
especially striking when comparing transfected and non-
transfected regions within the same denervated muscle
(Fig. 6c). These data show that HDAC4 nuclear accumulation
is markedly decreased by Mrf4 RNAi. On the other hand, protein
levels of HDAC4 remained unchanged, with similar increases
observed in both knockdown and control muscles after
denervation (Fig. 6e).
Mrf4 RNAi and caMEF2 cause mouse muscle hypertrophy. In
contrast to the results reported here, no signiﬁcant effect on
muscle ﬁbre size was previously described in an Mrf4 knockout
mouse model18 nor in transgenic mice overexpressing a MEF2C-
VP16 chimera19. To determine whether this discrepancy reﬂects a
species difference or is due to gene inactivation in the adult rather
than in the embryo, we performed electroporation experiments in
adult mouse muscles. As shown in Supplementary Fig. 9a,b, the
two major effects of MRF4 knockdown, namely myoﬁbre growth
and activation of the MEF2 reporter, were also evident in
transfected adult mouse muscles. Myoﬁbre hypertrophy was also
induced by caMEF2 (Supplementary Fig. 9c,d). These results
indicate that muscle ﬁbre size is also controlled by the MRF4–
MEF2 axis in adult mouse muscles.
We also performed chromatin immunoprecipitation (ChIP)
assays on mouse muscles to determine whether endogenous
MRF4 is present on MEF2-binding sites in muscle gene
promoters. ChIP assays were performed in denervated muscles,
a condition where a greater MRF4 binding would be predicted. As
shown in Supplementary Fig. 10, MRF4 was readily detected on
the promoters of MEF2 target genes, Abra and Glut4.
Importantly, the promoter of Abra does not contain any E-box
in the ampliﬁed region. The speciﬁcity of this result is supported
by the ﬁnding that no MRF4 binding was detected in muscles
from Mrf4 knockout mice.
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Discussion
The myogenic regulatory factors are well known to play key roles
during embryonic and fetal myogenesis, and in satellite cell-
mediated regeneration in adult muscle, however, their role in
adult muscle ﬁbres is unknown. This is an especially important
issue in the case of MRF4, the expression of which undergoes a
marked upregulation during late fetal and postnatal development.
The unexpected ﬁndings reported here provide a novel
interpretation of the role of MRF4 in adult muscle ﬁbres. We
show ﬁrstly that Mrf4 RNAi causes ﬁbre hypertrophy and
prevents denervation-induced atrophy, indicating that MRF4 acts
as a negative regulator of muscle growth, and secondly that this
effect is mediated by the transcriptional activation function of
MEF2 which acts as a positive regulator of growth. Our data lead
to a model in which in normal homeostasis the genes required for
the hypertrophic response are held in check by MRF4 working to
repress activation by MEF2. When this balance is disturbed and
the repression by MRF4 is lifted, MEF2 drives the transcription of
the gene set required for hypertrophy, leading to increased
protein synthesis and ﬁbre growth. Myoﬁbre hypertrophy
induced by Mrf4 RNAi occurred in transfected ﬁbres from both
fast and slow muscles. A similar effect was observed in
regenerating muscle, in which muscle ﬁbre growth was
accelerated, and in denervated muscles, in which muscle atrophy
was prevented. These results are somewhat surprising as no
obvious effect on ﬁbre size in fast and slow limb muscles was
described in the one Mrf4 knockout allele compatible with
survival18. This discrepancy may be due to compensatory effects
that arise when the gene is deleted from early embryonic stages
and thus an entire transcriptional programme is altered
throughout development. Indeed, it was previously reported
that muscle ﬁbre growth during regeneration is retarded in a line
of transgenic mice overexpressing MRF4 (ref. 20). The increase in
muscle growth induced by Mrf4 RNAi is due to elevated protein
synthesis, as determined by the increased amount of puromycin-
labelled peptides, in agreement with other models of muscle
hypertrophy9. However, further studies, including analyses of
protein degradation pathways, are required to deﬁne the changes
in protein turnover induced by Mrf4 RNAi and the signalling
pathways involved. Indeed, we found that the ubiquitin ligase
MURF1, which is usually associated with muscle atrophy, is also
upregulated by Mrf4 RNAi at the transcript level (not shown).
This is not surprising, as other models of muscle hypertrophy are
accompanied by an increase in both protein synthesis and
degradation21, possibly in relation with the reprogramming of
gene expression and remodelling of muscle structure induced by
muscle growth.
MEF2 transcription factors are known to be essential for
myogenesis both in vitro13,22 and in vivo during development23
and during muscle regeneration22. However, MEF2 factors have
not been associated with muscle hypertrophy in adult skeletal
muscle, although they are known to be involved in cardiac muscle
hypertrophy24. Several lines of evidence support a major role for
MEF2 factors in mediating the effect of MRF4 knockdown on
muscle hypertrophy. First, the top-ranking gene set enriched in
both innervated and denervated muscles transfected with MRF4
shRNA is comprised of genes regulated by MEF2 factors. Second,
co-immunoprecipitation assays support the existence of a
physical interaction between MRF4 and MEF2 factors. Third,
MEF2 transcriptional activity is strongly stimulated by Mrf4
RNAi and repressed by MRF4 overexpression, whereas opposite
effects are produced by myogenin overexpression, in agreement
with previous studies in cultured muscle cells11. Finally, the
increase in myoﬁbre size induced by Mrf4 RNAi is prevented by
dominant negative MEF2, while constitutively active MEF2 is able
to induce myoﬁbre hypertrophy in adult muscle. Thus MEF2
appears to be both necessary and sufﬁcient to mediate Mrf4
knockdown-induced muscle hypertrophy. Taken together, our
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results suggest that MRF4, unlike MyoD and myogenin, acts to
repress MEF2 transcriptional activity rather than to stimulate it.
Previous studies showed that MRF4, unlike MyoD and myogenin,
is not able to transactivate the promoters of many muscle genes,
in cultured mammalian muscle cells25,26.
The results of the present study show that MRF4 RNAi in adult
muscles leads to an increase in MEF2 transcriptional activity with
upregulation of both fast and slow skeletal muscle genes and,
surprisingly, also cardiac and smooth muscle genes. MEF2 is
known to be essential for skeletal, cardiac and smooth muscle
myogenesis27. In developing zebraﬁsh skeletal muscles, MEF2
factors were shown to control the expression of both fast and slow
myosins and other thick ﬁlament proteins28. In mice, muscle-
speciﬁc knockout of Mef2c or Mef2d causes a partial slow-to-fast
switch in mouse soleus, whereas transgenic mice overexpressing a
hyperactive Mef2c show an increased proportion of slow ﬁbres19.
On the other hand, both fast and slow muscle genes were
downregulated in cultured satellite cells after triple knockout of
Mef2a, c and d genes using tamoxifen-inducible Cre recombinase
driven by the satellite cell-speciﬁc Pax7 promoter22. Indeed, the
most downregulated Myh genes in MEF2-deﬁcient muscle cells
were Myh4 and Myh1, coding for the fast MyHC-2B and 2X,
respectively, which are also among the most upregulated genes
after MRF4 knockdown. The ﬁnding that cardiac and smooth
muscle genes are also induced by MRF4 knockdown could reﬂect
the fact that the potential role of MEF2 as a global regulator of
multiple muscle differentiation programs is restrained by MRF4
in adult skeletal muscle.
We have shown that the muscle-speciﬁc transcription factor
MRF4 inhibits muscle growth in both regenerating and adult
skeletal muscle, and have provided evidence that this effect is
mediated by a repressive action of MRF4 on the positive
transcriptional activity of MEF2. MRF4 is not a repressor
per se, therefore we suggest that it acts by affecting the function
of a MEF2 repressor. HDAC4 is the best characterized MEF2
repressor, which shuttles between the cytoplasm and the nucleus
and once in the nucleus associates with MEF2 factors and
represses their transcriptional activity, whereas HDAC4 nuclear
export leads to MEF2 activation16,17,29. HDAC4 appears to be
involved in MRF4-dependent MEF2 repression because its
nuclear localization in adult skeletal muscle is impaired by Mrf4
knockdown. It is known that HDAC4 enzymatic activity is
dependent on a multiprotein complex containing class I HDACs,
like HDAC3, and co-repressors, such as NCoR1 (nuclear receptor
co-repressor 1)30. Interestingly, a muscle-speciﬁc knockout of
NCoR1 leads to the activation of MEF2 and the induction of
muscle hypertrophy, among other phenotypes31. The
demonstration that MRF4 binds MEF2 and is found on MEF2
sites in muscle gene promoters suggests that MRF4 is a key
component, together with HDAC4 and NCoR1, of the
multiprotein repressive complex that regulates the activity of
the pro-hypertrophic transcription factor MEF2. The loss of
MRF4 might lead to a destabilization of the complex with a
consequent increase in MEF2 transcriptional activity, which may
well be mediated by increased acetylation of MEF2 consequent
upon the relocation of HDAC4 to the cytoplasm. The interactions
between MRF4 and the other components of the repressive
complex and the mechanism leading to HDAC4 nuclear export
remain to be established.
The suggested role of HDAC4 in mediating MRF4-dependent
derepression of MEF2 activity differs from the previously
described role of HDAC4 in controlling neurogenic muscle
atrophy via myogenin. Denervation causes upregulation and
nuclear accumulation of HDAC4 (ref. 32) and HDAC4
knockdown prevents denervation-induced myogenin
upregulation, acting via the corepressor Dach2 (refs 33,34). The
ﬁnding that mice lacking both HDAC4 and HDAC5 in skeletal
muscle are resistant to muscle atrophy upon denervation supports
the notion that the HDAC4–Dach2–myogenin pathway controls
denervation atrophy8. However, it is unlikely that this pathway is
implicated in the effect of Mrf4 knockdown because the
expression of myogenin is increased but that of HDAC4 is
unchanged by Mrf4 knockdown in both innervated and
denervated muscle. In addition, the changes in gene expression
induced by Mrf4 knockdown are very similar in innervated and
denervated muscle. Finally, another study suggested an alternative
pathway, dependent on HDAC4-MAP kinase crosstalk and
independent of myogenin induction, to connect HDAC4 to the
muscle atrophy programme35. This pathway is also unrelated to
the MRF4–MEF2 axis described here, because it involves the
deacetylation and activation of a key MAP3 kinase, MEKK2,
whereas the conserved histone deacetylase domain of HDAC4 is
completely dispensable for MEF2 repression36.
Our ﬁnding that muscle growth can be induced in adult
skeletal muscle by lifting MRF4-mediated repression and thus
activating MEF2 transcriptional activity might provide a new
strategy to combat muscle wasting. We have shown here that
denervation atrophy can be inhibited by activated MEF2 and it
will be of interest to determine whether this also occurs in other
conditions of muscle atrophy, including sarcopenia and cachexia.
Current treatments for muscle wasting, such as those based on
the inhibition of the type-II activin receptors, are non-ideal, given
the lack of tissue speciﬁcity and the contrasting effects of the
ligands binding these receptors. Indeed, recent studies indicate
that the disruption of the activin pathway may be potentially
deleterious in cardiac and skeletal muscle37,38. By contrast, MRF4
is exclusively expressed in skeletal muscle, not in heart or any
other tissue, thus providing a unique tissue-speciﬁc target.
Pharmacological treatments aimed at downregulating MRF4
expression, disrupting MRF4–MEF2 interactions or modulating
corepressor function may thus be viable approaches to maintain
muscle mass and prevent muscle wasting.
Methods
Animals and in vivo experiments. Experiments were performed in 6-week-old
male Wistar rats (about 150 g) or 2-month-old male CD1 mice (about 30 g). EDL
and soleus muscles were exposed in anaesthetised animals and injected with
plasmid DNA (30 mg in 50 ml saline). Injection was followed by electroporation
with stainless steel electrodes connected to an ECM830 BTX porator (Genetronics)
with the following settings: six pulses of 20ms each and 200-ms interval, voltage
adjusted to the thickness of the leg (220V cm 1). For transfection of regenerating
muscles, plasmid DNA (30 mg in 20% sucrose) was directly injected into the
muscles at day 3 after bupivacaine treatment without electroporation39.
Denervation was achieved by cutting the sciatic nerve high in the thigh. Muscles
were removed 7 or 14 days after transfection, frozen in isopentane cooled in liquid
nitrogen, and stored at  80 C. Activation of transfected MEF2-VP16-ER was
induced by injecting tamoxifen 30mg kg 1 in sunﬂower oil every other day for
seven days. For puromycin experiments and microarray analyses, soleus muscles
were chosen because they consistently showed a much greater efﬁciency of gene
transfer after electroporation compared to EDL muscles. We ﬁrst screened
transfected soleus muscles by GFP ﬂuorescence to identify those muscles with the
highest transfection efﬁciency and discarded the proximal and distal portions close
to the tendons, which are generally poorly transfected. The top three transfected
muscles from each of the four groups, that is, innervated and denervated M1, and
innervated and denervated LacZ, were thus selected. All experimental procedures
were performed according to the European Commission guidelines and were
approved by the local ethical committee and the relevant Italian authority
(Ministero della Salute, Ufﬁcio VI), in compliance of Italian Animal Welfare Law
(Law n 116/1992 and subsequent modiﬁcations) and complying with the Directive
2010/63/EU of the European Parliament. Animals were anaesthetized by ip
injection of a mixture of Zoletil 100 (Zolazapam and Tiletamine, 1:1, 10mg kg 1)
and Xilor (Xilazine 2%, 0.06ml kg 1), or by using an isoﬂurane vaporizer
maintained at 2% isoﬂurane, 1 lm 1 oxygen.
Cell culture and transfection. HEK-293 cells (ATCC) were cultured in DMEM
with 10% fetal bovine serum in a humidiﬁed incubator at 37 C with 5% CO2 and
transfected using Lipofectamine2000 (Invitrogen) and following the procedure
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recommended by the manufacturer. Cultures were tested for mycoplasma con-
tamination. Cell lysates were prepared and analysed 48 h after transfection.
Muscle and cell lysate preparation. For total muscle lysates, about 25 sections
(20 mm thick) of muscles were lysed in Laemmli buffer (10% w/v glycerol, 5% w/v
b-mercaptoethanol, 2.3% w/v SDS, 62.5mM Tris-HCl containing ‘complete’
protease inhibitor cocktail (Roche, one tablet per 1ml)). Homogenates were
sonicated for 5 s. HEK-293 cells were lysed in RIPA buffer containing ‘complete’
protease inhibitor cocktail.
Western blotting and co-immunoprecipitation assays. Lysates (30mg) were
heated in SDS sample buffer and subjected to SDS–PAGE and electrotransfer to
nitrocellulose membranes. Membranes were pre-incubated for 16 h at 4 C in
50mM Tris, pH 7.5, 150mM NaCl, and 0.1% Tween (TBST) containing 5%
skimmed milk. Antibodies were diluted in TBST. Detection of proteins was per-
formed using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad)
and the enhanced chemiluminescence reagent (Pierce Biotechnology, USA). For
co-immunoprecipitation experiments, Myc-tagged MRF4 or myogenin were
transfected in HEK-293 cells in presence or absence of Flag-tagged MEF2C.
All constructs were co-transfected with a plasmid coding for E47 protein and cells
were lysed after 24 h. Immunoprecipitations with anti-Myc or anti-Flag antibodies
were performed on cell lysates with Immunocruz IP/WB Optima System (Santa
Cruz) using the procedure recommended by the manufacturer.
Uncropped scans of all the autoradiographies shown in this work are reported
in Supplementary Fig. 11.
In vivo protein synthesis assays. Analysis of protein synthesis was performed
using a nonradioactive technique as described40. In brief, rats were anaesthetized
and injected i.p. with 0.04 mmol g 1 puromycin exactly 30min before removal of
muscles. Transfected muscles were ﬁrst examined by GFP ﬂuorescence to identify
regions showing the best gene transfer. Muscle homogenates were processed for
immunoblotting analysis using the 12D10 monoclonal antibody, speciﬁc for
puromycin10.
Immunoﬂuorescence and ﬁbre size measurement. About 10mm thick trans-
versal muscle sections were processed for immunoﬂuorescence using standard
conditions. Immunoﬂuorescence was performed on unﬁxed muscle cryosections
for MyHC and cardiac troponin I staining. For MRF4 staining a ﬁxation step with
4% paraformaldehyde (PFA), 10min at room temperature, was performed before
primary antibody incubation. Sections were permeabilized with 0.2% Triton X-100
for 10min at room temperature. DyLight488-labelled secondary antibodies (Jack-
son laboratories) were used. Images were collected with an epiﬂuorescence Leica
DM5000B microscope equipped with a DFC 300FX camera. Cross-sectional area of
individual ﬁbres was manually outlined using ImageJ NIH (http://imagej.nih.gov/ij).
For HDAC4 localization, sections of muscles transfected with M1 and GFP were
ﬁxed in PFA and stained for HDAC4 and dystrophin. Transfected ﬁbres and their
myonuclei were identiﬁed by GFP and DAPI staining. The HDAC4 ﬂuorescence
intensity of pixels for each transfected ﬁbre cross-section were quantitated using
ImageJ NIH software. For each ﬁbre the percentage of nuclear HDAC4 was
calculated by the ratio of the ﬂuorescence intensity of endogenous HDAC4 in
myonuclei divided by the total ﬂuorescence intensity of the same ﬁbre
(nuclei/cytoplasmþ nuclei). Results are expressed as the mean±s.e.m.
Antibodies. The following antibodies were purchased from Santa Cruz Bio-
Technology: Myf6 C-19 rabbit polyclonal (sc-301 X; 1:500); myogenin monoclonal
(sc-12732; 1:1,000); b-Tubulin rabbit polyclonal (sc-9104; 1:5,000), green ﬂuor-
escent protein rabbit polyclonal (sc-8334; 1:500), HDAC4 rabbit polyclonal
(sc-11418; 1:500), VP16 monoclonal (sc-7545; 1:100). The c-myc 9E10 monoclonal
antibody (prod. Num 116672030001; 1:500) was from Roche, the ﬂag M2 (F1804;
1:2,000) monoclonal antibody and the anti-puromycin 12D10 (MABE343; 1:5,000)
monoclonal antibody were from Merk-Millipore, and anti-dystrophin (MANDRA 1)
from Developmental Studies Hybridoma Bank (DSHB; 1:1,000). Green Fluorescent
Protein rabbit polyclonal (for immunoﬂuorescence staining) was purchased from
Invitrogen (A11122; 1:200). The following monoclonal antibodies are homemade
and are distributed by DSHB: SC-71 (MyHC-2A; 1:100), BF-F3 (MyHC-2B; 1:100),
BF-G6 (MyHC-emb; 1:200), BF-B6 (MyHC-neo; 1:500), BA-G5 (MyHC-a cardiac;
1:500), TI-1 (troponin I cardiac 1:500)41–45.
RNAi-mediated gene silencing. The sequences of Mrf4 and Myog genes were
retrieved and analysed. The target sequences were selected on unique regions with
respect to the others MRFs. Target oligos were designed by using the criteria
deﬁned by Reynolds et al.46. We selected at least 4 oligos per gene on the basis of a
speciﬁcity screening performed with BLAST analysis. The selected oligos were
cloned into the pSUPER vector. We co-transfected the epitope-tagged cDNA
together with each pSUPER construct. As a control, we used pSUPER constructs
targeting LacZ. To exclude that the observed downregulation of Mrf4 or MyoG
could be due to off-target effects, we selected at least two sequences with high
silencing efﬁciency for each gene, and rescue experiments were performed by co-
transfecting RNAi-resistant cDNAs. The sequences used are indicated below with
the corresponding position on the targeted Mrf4 or MyoG sequence:
Mrf4 M1: GCAAGACCTGCAAGAGAAA (National Center for Biotechnology
Information (NCBI) Reference Sequence NM_ 008657).
Mrf4 M2: GCGAAAGGAGGAGGCTTAA (National Center for Biotechnology
Information (NCBI) Reference Sequence NM_ 013172).
MyoG MG1: CCATGCCCAACTGAGATTG (National Center for
Biotechnology Information (NCBI) Reference Sequence NM_ 017115).
MyoG MG2 GAGAAGCACCCTGCTCAAC (National Center for
Biotechnology Information (NCBI) Reference Sequence NM_ 017115).
RNA isolation and qPCR. For quantitative real-time-PCR assays, total RNA was
puriﬁed using SV Total RNA Isolation (Promega, Madison, WI, USA) and its
integrity was assessed by capillary electrophoresis (Agilent, Santa Clara, CA, USA).
RNA (400 ng) was converted to cDNA using random primers and Superscript III
(Invitrogen, Carlsbad, CA, USA). Ampliﬁcation was carried out in triplicates with a
7900HT Fast Real Time PCR System (Applied Biosystems) using the Fast SYBR
Green RT-PCR kit (Applied Biosystems) and a standard 2-step protocol. The
primers speciﬁc for each gene were designed and analysed with Primer3 (freeware)
and Vector NTI (Invitrogen, freeware). Identity of the amplicons was conﬁrmed by
their dissociation proﬁles and gel analysis. Quantitative PCR standard curves were
constructed by using serial dilutions of muscle cDNAs, using at least four dilution
points and the efﬁciency of all primer sets was between 1.8 and 2.2. The data were
normalized against Rplp0 housekeeping gene. Primers are listed in Supplementary
Table 2.
Plasmids. The plasmids were prepared using Qiagen Maxiprep Kit (Invitrogen)
according to the manufacturer’s instructions. pSUPER vector in which shRNAs
were inserted under the control of the polymerase-III H1-RNA gene promoter was
from Oligoengine. pcDNA3 was from Invitrogen, Tk-Renilla from Promega. Rat
Mrf4 and MyoG were from Addgene; human Mrf4 from Origene. Myc-Mrf4 was
obtained by subcloning mouse Mrf4 in pcDNA3.1Myc-HisB. Mef2-Flag and
dominant negative MEF2 (dnMEF2) were kindly provided by Windt. The Mef2
reporter plasmid, kindly provided by Rhonda Bassel-Duby, contains three copies of
the Mef2 element from the muscle desmin gene promoter, followed by the luci-
ferase gene. Mrf4-MyoG chimeras were a kind gift of Moss47. MEF2-VP16-ER
(caMEF2) and MEF2DDBDVP16-ER (D-caMEF2: caMEF2 with deleted DNA-
binding domain) plasmids were kindly provided by M. Greenberg14.
Luciferase assay. For luciferase assay we used the Dual luciferase kit E1960,
Promega Corp., Madison WI, USA. Muscles were crushed with a pestle and mortar
cooled with liquid nitrogen. Powder was weighted and added with 2.5 ml of lysis
buffer for each mg of tissue. Lysates were frozen with liquid nitrogen and thawed at
4 C twice. Lysates were then centrifuged for 20min at 13,000 r.p.m. at 4 C, and
supernatants were collected. Ten microliter of supernatant were analysed according
to the manifacturer’s instructions.
Chromatin immunoprecipitation and real-time qPCR. ChIP-qPCR of mouse
gastrocnemius muscle from wild-type and Mrf4 knockout18 mice was performed
with sonicated nuclear extract prepared from formaldehyde-crosslinked tissue
according to Nelson et al.48 using anti-MRF4 antibody (Proteintech 11754) or
rabbit IgG (Santa Cruz 2027x). Immunoprecipitated DNA was decrosslinked,
puriﬁed and used for quantitative real-time PCR. Primer sequences used are the
following: Abra_Promoter_FW CCAGCTAAAGGGGAATGTGGT;
Abra_Promoter_RV TAGTTTCCACCGTCACAGGC; Glut4_Promoter FW GAC
ACCCGGGACCTGACATT; Glut4_Promoter RV CATGTACTTGCCAGGGTA
CGG; Hprt_intron_FW CAACCACTTACTTAGAGGTACT; Hprt_intron_RV TT
AGCAATATGGACTGTGAGGG.
Microarray analysis and computational tools. For microarray experiments, three
biological replicates for each group, including innervated and denervated MRF4
RNAi (M1) and innervated and denervated LacZ RNAi, were hybridized on
Affymetrix Rat Genome 230 2.0 arrays. Isolated total RNA samples were processed
as recommended by Affymetrix (Affymetrix, Inc., Santa Clara, CA). All data
analyses were performed in R (version 2.15.0) using Bioconductor libraries (BioC
2.7) and R statistical packages. Probe level signals were converted to expression
values using robust multi-array average procedure RMA49 of Bioconductor affy
package and Brainarray rat2032rnentrezg custom CDF ﬁles (http://
brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF). Statistically
signiﬁcant differences in gene expression between M1 and LacZ samples were
determined using the empirical Bayes moderated t-test in the Bioconductor limma
package50. In limma, we selected differentially expressed genes setting a fold
changer±2 and an adj. P valuer0.05 after multiple testing corrections51. The
expression of a select panel of genes was validated using real time quantitative
reverse transcription PCR (qRT-PCR). We used Gene Set Enrichment Analysis
(GSEA, http://http://www.broadinstitute.org/gsea52) to determine whether a priori
deﬁned sets of genes showed statistically signiﬁcant differences between the M1
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and LacZ samples. Enrichment analysis was performed on gene sets derived from
the Biological Process Ontology (C5, CC: GO cellular component) and from the
TRANSFAC transcription factor binding site (C3, TFT: transcription factor targets)
categories of the Molecular Signatures Database (http://www.broadinstitute.org/
gsea/msigdb/index.jsp). The GO biological set was supplemented with a list of
sarcomeric myosins speciﬁcally expressed in skeletal muscle (Supplementary
Table 4). Gene sets were deﬁned as signiﬁcantly enriched if the FDR waso5%
when using Signal2Noise as metric and 1,000 permutations of gene set.
Statistical analysis. Data are presented as mean±s.e.m. Statistical signiﬁcance
was determined using two-tailed Student’s t-test with a signiﬁcance threshold of
0.05 (*Po0.05; **Po0.01; ***Po0.001). Tests were applied upon veriﬁcation of
the test assumptions (for example, normality). For the measurement variables used
to compare different conditions, the variance was similar between the groups.
Animals were randomly allocated to the different experimental groups. Investi-
gators were blinded when transfecting animals and when assessing the outcome of
experiments. Exclusion criteria for rats/mice were pre-determined: animals were
excluded from analysis in case of cannibalism, sickness, or poor transfection efﬁ-
ciency (less than 10 transfected ﬁbres). Minimum sample size was determined
using size power analysis methods for a priori determination, based on the stan-
dard deviation and effect size previously obtained using the same experimental
methods employed in the study. We used G*Power Software with alpha¼ 0.05 and
a power of 0.8 to determine the needed sample size.
Data availability. Microarray data are deposited in the NCBI Gene Expression
Omnibus (GEO) under accession code GSE67069. The data that support the
ﬁndings of this study are available from the corresponding author upon request.
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